MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Emergent BioSolutions

< Previous 1 2 3 Next >
News headline image
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Announces Stock Repurchase Program
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS HKMPY
News headline image
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story